Polycystic ovarian syndrome during puberty and adolescence

Molecular and Cellular Endocrinology

Volumn 373, Issue 1-2, 2013, Pages 61-67

  Williams, Rachel M ^a   Ong, Ken K ^b   Dunger, David B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

Author keywords

Adolescence; Insulin resistance; Ovarian hyperandrogenism; PCOS; Puberty

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIANDROGEN; CYPROTERONE ACETATE; DROSPIRENONE PLUS ETHINYLESTRADIOL; FLUTAMIDE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SPIRONOLACTONE; ANTIDIABETIC AGENT;

ADOLESCENCE; ADOLESCENT; ADRENAL TUMOR; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; CONGENITAL ADRENAL HYPERPLASIA; DIFFERENTIAL DIAGNOSIS; FEMALE FERTILITY; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER TOXICITY; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION; PRIORITY JOURNAL; PROSTATE CANCER; PUBERTY; DRUG EFFECTS; ECHOGRAPHY; FEMALE; METABOLISM; OVARY; PATHOPHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; DRUG EFFECT;

ADOLESCENT; ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OVARY; OVULATION; POLYCYSTIC OVARY SYNDROME; PUBERTY; THIAZOLIDINEDIONES;

EID: 84878114328     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.01.005     Document Type: Article

References (70)

1. Ahmed, M.L., 2008. Endocrine changes during puberty. PhD Thesis: Pubertal Growth in Diabetic Children.
2. Ahmed M.L., Ong K.K., Morrell D.J., Cox L., Drayer N., Perry L., Preece M.A., Dunger D.B. Longitudinal study of leptin concentrations during puberty: sex differences and relationship to changes in body composition. J. Clin. Endocrinol. Metab. 1999, 84:899-905.
3. Allen H.F., Mazzoni C., Heptulla R.A., Murray M.A., Miller N., Koenigs L., Reiter E.O. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab. 2005, 18:761-768.
4. Amiel S.A., Caprio S., Sherwin R.S., Plewe G., Haymond M.W., Tamborlane W.V. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J. Clin. Endocrinol. Metab. 1991, 72:277-282.
5. Apter D., Vihko R. Premenarcheal endocrine changes in relation to age at menarche. Clin. Endocrinol. (Oxf) 1985, 22:753-760.
6. Arslanian S., Suprasongsin C. Testosterone treatment in adolescents with delayed puberty: changes in body composition, protein, fat, and glucose metabolism. J. Clin. Endocrinol. Metab. 1997, 82:3213-3220.
7. Arslanian S.A., Lewy V., Danadian K., Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance. amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J. Clin. Endocrinol. Metab. 2002, 87:1555-1559.
8. Azziz R., Ehrmann D.A., Legro R.S., Fereshetian A.G., O'Keefe M., Ghazzi M.N. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil. Steril. 2003, 79:932-937.
9. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., Witchel S.F. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 2009, 91:456-488.
10. Balen A.H., Laven J.S., Tan S.L., Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum. Reprod. Update 2003, 9:505-514.
11. Bridger T., MacDonald S., Baltzer F., Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch. Pediatr. Adolesc. Med. 2006, 160:241-246.
12. Bridges N.A., Cooke A., Healy M.J., Hindmarsh P.C., Brook C.G. Standards for ovarian volume in childhood and puberty. Fertil. Steril. 1993, 60:456-460.
13. Caprio S., Plewe G., Diamond M.P., Simonson D.C., Boulware S.D., Sherwin R.S., Tamborlane W.V. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J. Pediatr. 1989, 114:963-967.
14. Carmina, E., Oberfield, S.E., Lobo, R.A., 2010 The diagnosis of polycystic ovary syndrome in adolescents. Am. J. Obstet. Gynecol. 203, 201 e1-5.
15. Creatsas G., Koliopoulos C., Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann. NY Acad. Sci. 2000, 900:245-252.
16. Diaz A., Laufer M.R., Breech L.L. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics 2006, 118:2245-2250.
17. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1996, 81:3299-3306.
18. Farooqi I.S. Leptin and the onset of puberty: insights from rodent and human genetics. Semin. Reprod. Med. 2002, 20:139-144.
19. Fauser, B.C., Tarlatzis, B.C., Rebar, R.W., Legro, R.S., Balen, A.H., Lobo, R., Carmina, E., Chang, J., Yildiz, B.O., Laven, J.S., Boivin, J., Petraglia, F., Wijeyeratne, C.N., Norman, R.J., Dunaif, A., Franks, S., Wild, R.A., Dumesic, D. and Barnhart, K., 2012. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 97, 28-38 e25.
20. Franks S., Layton A., Glasier A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum. Reprod. 2008, 23:231-232.
21. Ganie M.A., Khurana M.L., Eunice M., Gupta N., Gulati M., Dwivedi S.N., Ammini A.C. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J. Clin. Endocrinol. Metab. 2004, 89:2756-2762.
22. Garmes H.M., Tambascia M.A., Zantut-Wittmann D.E. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol. Endocrinol. 2005, 21:317-323.
23. Glueck C.J., Morrison J.A., Friedman L.A., Goldenberg N., Stroop D.M., Wang P. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. Metabolism 2006, 55:508-514.
24. Goodarzi M.O., Dumesic D.A., Chazenbalk G., Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011, 7:219-231.
25. Hickey M., Balen A. Menstrual disorders in adolescence. investigation and management. Hum. Reprod. Update 2003, 9:493-504.
26. Hickey M., Doherty D.A., Atkinson H., Sloboda D.M., Franks S., Norman R.J., Hart R. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum Reprod 2011, 26:1469-1477.
27. Hoeger K., Davidson K., Kochman L., Cherry T., Kopin L., Guzick D.S. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab. 2008, 93:4299-4306.
28. Ibanez L., de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J. Clin. Endocrinol. Metab. 2004, 89:1592-1597.
29. Ibanez L., Potau N., Virdis R., Zampolli M., Terzi C., Gussinye M., Carrascosa A., Vicens-Calvet E. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 1993, 76:1599-1603.
30. Ibanez L., Dimartino-Nardi J., Potau N., Saenger P. Premature adrenarche - normal variant or forerunner of adult disease?. Endocr. Rev. 2000, 21:671-696.
31. Ibanez L., Valls C., Potau N., Marcos M.V., de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J. Clin. Endocrinol. Metab. 2000, 85:3526-3530.
32. Ibanez L., Potau N., Marcos M.V., de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J. Clin. Endocrinol. Metab. 2000, 85:3251-3255.
33. Ibanez L., Valls C., Marcos M.V., Ong K., Dunger D.B., De Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment. J. Clin. Endocrinol. Metab. 2004, 89:4331-4337.
34. Ibanez L., Ferrer A., Ong K., Amin R., Dunger D., de Zegher F. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J. Pediatr. 2004, 144:23-29.
35. Ibanez L., Jaramillo A., Ferrer A., de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum. Reprod. 2005, 20:1833-1836.
36. Ibanez L., Lopez-Bermejo A., del Rio L., Enriquez G., Valls C., de Zegher F. Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. J. Clin. Endocrinol. Metab. 2007, 92:1710-1714.
37. Ibanez L., Lopez-Bermejo A., Diaz M., Enriquez G., Valls C., de Zegher F. Pioglitazone (7.5mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clin. Endocrinol. (Oxf) 2008, 68:317-320.
38. Ibanez L., Lopez-Bermejo A., Diaz M., Enriquez G., del Rio L., de Zegher F. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin. Endocrinol. (Oxf) 2009, 71:351-357.
39. Jonard S., Robert Y., Dewailly D. Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum. Reprod. 2005, 20:2893-2898.
40. La Marca A., Pati M., Orvieto R., Stabile G., Carducci Artenisio A., Volpe A. Serum anti-mullerian hormone levels in women with secondary amenorrhea. Fertil. Steril. 2006, 85:1547-1549.
41. Laggari V., Diareme S., Christogiorgos S., Deligeoroglou E., Christopoulos P., Tsiantis J., Creatsas G. Anxiety and depression in adolescents with polycystic ovary syndrome and Mayer-Rokitansky-Kuster-Hauser syndrome. J. Psychosom. Obstet. Gyn. 2009, 30:83-88.
42. Lewy V.D., Danadian K., Witchel S.F., Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J. Pediatr. 2001, 138:38-44.
43. Marshall W.A., Tanner J.M. Variations in pattern of pubertal changes in girls. Arch. Dis. Child. 1969, 44:291-303.
44. Martinez F., Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur. J. Contracept. Reprod. Health Care 2007, 12:97-106.
45. Mastorakos G., Koliopoulos C., Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil. Steril. 2002, 77:919-927.
46. Mastorakos G., Koliopoulos C., Deligeoroglou E., Diamanti-Kandarakis E., Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil. Steril. 2006, 85:420-427.
47. Ornstein, R.M., Copperman, N.M., Jacobson, M.S., 2011. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J. Pediatr. Adolesc. Gynecol.
48. PCOS, 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19, 41-7.
49. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 27, 14-24.
50. Rautio K., Tapanainen J.S., Ruokonen A., Morin-Papunen L.C. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum. Reprod. 2006, 21:1400-1407.
51. Reinehr, T., Widhalm, K., l'Allemand, D., Wiegand, S., Wabitsch, M. and Holl, R.W., 2009. Two-year follow-up in 21,784 overweight children and adolescents with lifestyle intervention. Obesity (Silver Spring) 17, 1196-9.
52. Rofey D.L., Szigethy E.M., Noll R.B., Dahl R.E., Lobst E., Arslanian S.A. Cognitive-behavioral therapy for physical and emotional disturbances in adolescents with polycystic ovary syndrome: a pilot study. J. Pediatr. Psychol. 2009, 34:156-163.
53. Rosenfield R.L., Ghai K., Ehrmann D.A., Barnes R.B. Diagnosis of the polycystic ovary syndrome in adolescence. comparison of adolescent and adult hyperandrogenism. J. Pediatr. Endocrinol. Metab. 2000, 13(Suppl 5):1285-1289.
54. Sciarra A., Cardi A., Di Silverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urol. Int. 2004, 72:91-98.
55. Seaman H.E., de Vries C.S., Farmer R.D. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum. Reprod. 2003, 18:522-526.
56. Seaman H.E., de Vries C.S., Farmer R.D. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK general practice research database. Pharmacoepidemiol. Drug Saf. 2004, 13:427-436.
57. Shah B., Parnell L., Milla S., Kessler M., David R. Endometrial thickness, uterine, and ovarian ultrasonographic features in adolescents with polycystic ovarian syndrome 2009, J. Pediatr. Adolesc. Gynecol.
58. Shayya R., Chang R.J. Reproductive endocrinology of adolescent polycystic ovary syndrome. Bjog 2010, 117:150-155.
59. Sir-Petermann T., Codner E., Maliqueo M., Echiburu B., Hitschfeld C., Crisosto N., Perez-Bravo F., Recabarren S.E., Cassorla F. Increased anti-Mullerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2006, 91:3105-3109.
60. Sir-Petermann T., Codner E., Perez V., Echiburu B., Maliqueo M., Ladron de Guevara A., Preisler J., Crisosto N., Sanchez F., Cassorla F., Bhasin S. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2009, 94:1923-1930.
61. Stanhope R., Adams J., Jacobs H.S., Brook C.G. Ovarian ultrasound assessment in normal children, idiopathic precocious puberty, and during low dose pulsatile gonadotrophin releasing hormone treatment of hypogonadotrophic hypogonadism. Arch. Dis. Child. 1985, 60:116-119.
62. Tang, T., Lord, J.M., Norman, R.J., Yasmin, E., Balen, A.H., 2009. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev, CD003053.
63. Teede H.J., Meyer C., Hutchison S.K., Zoungas S., McGrath B.P., Moran L.J. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy 2008, Fertil. Steril.
64. Tfayli H., Ulnach J.W., Lee S., Sutton-Tyrrell K., Arslanian S. Drospirenone/Ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 2011, 96:1311-1319.
65. Thole Z., Manso G., Salgueiro E., Revuelta P., Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol. Int. 2004, 73:289-295.
66. Treloar A.E. Menstrual cyclicity and the pre-menopause. Maturitas 1981, 3:249-264.
67. van Hooff M.H., Voorhorst F.J., Kaptein M.B., Hirasing R.A., Koppenaal C., Schoemaker J. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum. Reprod. 2004, 19:383-392.
68. Venturoli S., Porcu E., Fabbri R., Pluchinotta V., Ruggeri S., Macrelli S., Paradisi R., Flamigni C. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr. Res. 1995, 38:974-980.
69. Vihko R., Apter D. Endocrine characteristics of adolescent menstrual cycles: impact of early menarche. J. Steroid. Biochem. 1984, 20:231-236.
70. Zawadzki J.K., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic Ovary Syndrom 1995, 377-384. Blackwell Scientific, Boston. A. Dunaif (Ed.).